-Introduction-
The healthcare industry is currently in a golden cycle of technological breakthroughs and capital layout, with high barrier innovation platforms and clinical landing projects becoming the core scarce assets in the market.

Continuing from the previous period, this period continues to consolidate 9 high-quality medical assets, covering high prosperity tracks such as brain computer interfaces, IVD diagnosis, cell therapy, high-end devices, cutting-edge delivery, and innovative drugs. All of them have core technological barriers, solid clinical/data verification, improved patent layout, and clear commercialization paths. Many of them have entered the certification, installation, and clinical stages, with significant investment value and industrial cooperation space.

---

We are now fully open to equity investment, mergers and acquisitions, BD cooperation, and global authorization docking for investment institutions, listed companies, and industry players!

We sincerely invite you to join hands to seize the dividends of medical innovation and build a win-win ecosystem for both industry and capital

The following is an introduction to medical assets for this period:

---

1、 Brain computer interface | AI driven mental health and brain health management platform

Centered around mental health and brain health management, this platform integrates brain signal monitoring devices, mental health models, and intelligent agent systems into a single product system, covering screening, risk warning, intervention recommendations, and long-term follow-up. The existing products have formed hospital monitoring equipment, lightweight terminals for home and school scenarios, and interface capabilities that can output to third-party hardware. The accuracy of emotion recognition has reached 92.4%, and the accuracy of home scenario warning has reached 98%. The platform has accumulated 140 million days of continuous monitoring data, over 5000 psychiatric samples, and more than 100000 hours of interactive data, while also laying out more than 15 invention patents.

On the commercial path, hospitals and schools are responsible for screening and acquiring customers, while households subscribe to undertake long-term services; The first stage covers mental health and adolescent scenarios, and later extends to elderly cognitive decline intervention and whole life cycle brain health management.

---

2、 IVD | Fully Homogeneous Chemiluminescence Diagnostic Platform

This is a new generation platform for immune chemiluminescence detection, characterized by full homogeneity, no cleaning, non-magnetic particles, and synchronized layout around “instrument+reagent”. The platform has obtained 18 registration certificates for tumor marker reagents and 1 registration certificate for a 300 speed analyzer. The 300 speed model has been installed and put into use, but it is still being promoted in areas such as thyroid function, myocardium, inflammation, and infectious diseases. Compared with the traditional magnetic particle pathway, the reaction steps are compressed from 12 steps to 5 steps, and the cost of reagents and materials is reduced by more than 30%. The 1600 speed single machine solution can also significantly reduce the investment in hospital instruments.

The latest product evaluation of chemiluminescence from the four global IVD giants is here! Roche, Abbott, Siemens, Beckman … – Zhihu

The external highlight is that it has both certified products and existing customer base, as well as the potential to continue expanding its menu and upgrading to high-speed models.

---

3、 Cell Therapy | Universal iPSC Cell Therapy Platform

The basic framework of “underlying cell platform+multiple transformation pipelines+GMP industrialization conditions” has been established around the development of universal iPSC cell drugs. The existing layout covers areas such as hair loss, Alzheimer’s disease, and liver cancer. The hair loss project has been implemented in the hospital through IIT, and 18 patents have been formed on the platform, including 10 invention patents. It is also equipped with approximately 4000 square meters of research and development space and 1000 square meters of GMP workshop. The team has integrated clinical hospitals, research institutes, and overseas iPSC research resources, and has the ability to undertake tasks from cell sources, functional cell research and development to downstream application transformation. As the iPSC track continues to heat up globally, assets with platforms, facilities, and multi project reserves are more likely to form sustained output and future cooperation space.

---

4、 Ophthalmic Instruments | Digital Fundus Laser Treatment Platform

This platform aims to replace domestic high-end ophthalmic laser equipment, with the core product being a new generation digital fundus laser treatment device, and synchronously layout digital slit lamps, illuminated contact lenses, and generative lasers.

The equipment revolves around true color surgical field display, eyeless visualization, precise laser control, and remote guidance teaching, making it more suitable for promotion and standardized training in primary hospitals. The core product has entered the registration stage, and the production line has also passed the quality system verification of three types of medical devices. The company also owns 34 patents, 10 software copyrights, and 7 trademarks. There are over 80 million domestic patients with retinal diseases, and the market space for ophthalmic laser equipment is clear. The platform can continue to expand to a wider range of energy source devices in the future.

---

5、 Digital Health | Non invasive Early Diagnosis, Self Inspection, and Continuous Monitoring Platform

This platform focuses on non-invasive health screening and continuous management in both home and community settings. Existing products include home early diagnosis devices, desktop early diagnosis devices, and continuous monitoring gowns.

The underlying capabilities come from multimodal detection of sound, light, electricity, and heat, big data modeling, and AI algorithms. We have accumulated over 150000 comparative data cases and continue to expand on existing non-invasive blood analysis technologies. The family early diagnosis device has formed a batch of products and started registration. The desktop prototype has been completed and data collection has been carried out. Its application scenarios cover major disease early screening, chronic disease management, postoperative rehabilitation, mental stress monitoring, and remote medical care. When it comes to external dissemination, the highlight of such assets lies in transforming some in-hospital testing scenarios into sustainable health management entrances for households and communities.

---

6、 Sensing and Control Devices | Invasive Device Low Temperature Sterilization Platform

Around the scene of invasive instruments such as endoscopes, this platform integrates ultrasound, ultraviolet, ozone, and patented sterilization solutions into the same low-temperature cleaning and sterilization process. The existing products can complete advanced disinfection in 13 minutes and complete sterilization in 30 minutes. The supporting sterilization solution has obtained the marketing authorization for imported sterilization labels and completed FDA related tests, strain simulation tests, and in hospital real use verification. The business model adopts “machines+consumables+drugs”, and after the equipment is deployed, it can sustainably drive subsequent consumption income. The three-year plan is to deploy 30000 units. The endoscopic market in China is about 30 billion yuan, and the global market is about 300 billion yuan. Against the backdrop of hospital infection control upgrades and stricter supervision, this type of rapid low-temperature sterilization equipment has a clear entry window for hospitals.

---

7、 Delivery Platform | Central Nervous System Nucleic Acid Nano Delivery Platform

 

This is a programmable delivery platform built around central nervous system drug delivery, which can carry DNA, RNA, proteins, and small molecule drugs, focusing on solving the problem of low delivery efficiency in deep brain and spinal cord tissues. The existing layout has covered brain delivery, spinal cord delivery, brain tumor and triple negative breast cancer, and formed a parallel structure of self research, cooperative development and authorized output. The existing data has validated the advantages of the platform in deep brain parenchymal delivery, and clear pharmacological signals have also been obtained in ALS models. When communicating externally, the focus of such platform assets is that they not only serve a single project, but also have the opportunity to continue extending to more central indications and more payload types.

---

8、 Delivery Platform | eCIS Programmable Protein Delivery Platform

The platform is based on the eCIS device to develop a new type of programmable protein delivery carrier, targeting intracellular delivery of large molecules such as protein drugs, gene editing tools, and transcription factors. The existing research has systematically elucidated the structure, loading, and delivery mechanism of eCIS, and completed the underlying patent and PCT layout. The relevant results have been published in Cell, Science China Life Sciences, and Science Advances. The platform can achieve cell recognition through tail fiber reprogramming, and can also adapt to different therapeutic tasks through payload programming. The validated protein payload range is 10-200 kDa. With the continuous increase in demand for gene editing and protein delivery, these low-level delivery tools that combine specificity, payload compatibility, and engineering potential have clear external cooperation and platform extension space.

---

9、 Innovative Medicine | Pan RAS (ON) Molecular Gel Small Molecule Platform

This project focuses on the development of Pan RAS (ON) molecular gel small molecule inhibitors driven by RAS mutations in solid tumors, covering various RAS driven tumors and drug resistance scenarios. At present, we have entered the clinical convergence stage after IND was approved. The existing model data shows that in the KRAS G12D/G12V related pancreatic cancer and colorectal cancer models, the tumor inhibition effect can be achieved at a lower dose, which is equivalent to that of similar controls, and the tumor regression trend has been observed. The project also has the potential to be used in combination with other pathways or immunotherapy regimens, and to derive molecules with ADC payload extension space. For the capital side, the highlight of these assets lies in their clear mechanism positioning, clear comparative advantages within the same category, and the existing small molecule R&D system and subsequent combination development space behind them.

The 9 major medical and health innovation assets gathered this time are all centered on cutting-edge technology, guided by clinical needs, and aimed at market growth. They cover innovative drugs, high-end devices, delivery platforms, and digital health tracks, and can fully adapt to capital investment, industrial mergers and acquisitions, cross-border business development, and commercial cooperation.

Collaboration docking channel!!!!

If you are an investment institution, pharmaceutical/device listed company, overseas BD team, or industry partner interested in the above projects, please scan the QR code below to add WeChat and seize innovation opportunities in the medical and health field together!

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.